# Propanc Biopharma, Inc.: Form 10-Q for the period ended Mar 31, 2013

- Company: [Propanc Biopharma, Inc.](/companies/ppcb.md) (CIK 1517681)
- Form: 10-Q
- Filed: 2013-05-20
- Accepted by EDGAR: May 20, 2013, 14:22 ET
- Period: 2013-03-31
- Accession: 0001354488-13-003018
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1517681/000135448813003018/ppch_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1517681/000135448813003018/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2013-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 9 months, 2012-07-01 to 2013-03-31 | $1.7k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2013-01-01 to 2013-03-31 | −$229.4k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2012-07-01 to 2013-03-31 | −$1.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2013-01-01 to 2013-03-31 | $1.4k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2012-07-01 to 2013-03-31 | $4.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2013-01-01 to 2013-03-31 | −$30 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2012-07-01 to 2013-03-31 | −$61.1k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2013-01-01 to 2013-03-31 | −$337.7k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2012-07-01 to 2013-03-31 | −$1.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 9 months, 2012-07-01 to 2013-03-31 | −$0.02 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2012-07-01 to 2013-03-31 | −$96.7k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Current assets | at 2013-03-31 | $423 | us-gaap:AssetsCurrent |
| Total assets | at 2013-03-31 | $4.1k | us-gaap:Assets |
| Current liabilities | at 2013-03-31 | $752.0k | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | at 2013-03-31 | −$747.8k | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 11,601 characters.

### Special Note Regarding Forward-Looking Statements

The following discussion should be read in conjunction with our unaudited consolidated financial statements, which are included elsewhere in this Quarterly Report on Form 10-Q (this "Report"). Certain statements in this Report concerning our business prospects or future financial performance, anticipated revenues, expenses, profitability or other financial items, estimates as to size, growth in or projected revenues, developments in industry regulations and the application of such regulations, expected outcomes of pending or potential litigation and regulatory actions, and our strategies, plans and objectives, together with other statements that are not historical facts, are "forward-looking statements" as that term is defined under the federal securities laws. In some cases, you can identify forward-looking statements by terminology such as "may," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. All of these forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update any such forward-looking statements. You should carefully review the risks described herein and in other documents we file from time to time with the Securities and Exchange Commission ("SEC"), including our Final Prospectus on Form 424b filed on December 16, 2011, particularly in the sections entitled "Risk Factors" and "Management’s Discussion and Analysis of Financial Condition and Results of Operations." Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.

### Company Overview

We are a research and development company whose primary activity is to develop new treatments for chronic diseases, in particular cancer. Since inception, substantially all of the efforts of the Company have been the development of new cancer treatments targeting high risk patients who need a follow-up, non-toxic, long-term therapy which prevents the cancer from returning and spreading. The Company is a development stage enterprise and has begun raising capital, financial planning, establishing sources of supply, and acquiring property and equipment. We have generated no revenue, have no cancer treatment products available to market and have no products which have reached the clinical trial stage. We require substantial additional financing to develop our products.

Propanc PTY LTD was incorporated in Melbourne, Victoria Australia on October 15, 2007. On November 23, 2010, Propanc Health Group Corporation was incorporated in the state of Delaware. In January 2011, Propanc Health Group Corporation acquired all of the outstanding shares of Propanc PTY LTD on a one-for-one basis making it a wholly-owned subsidiary.

### Critical Accounting Estimates

Below the Company will provide a discussion of its more subjective accounting estimation processes for purposes of (i) explaining the methodology used in calculating the estimates, (ii) the inherent uncertainties pertaining to such estimates, and (iii) the possible effects of a significant variance in actual experience, from that of the estimate, on the Company’s financial condition. Estimates involve the employ of numerous assumptions that, if incorrect, could create a material adverse impact on the Company’s results of operations and financial condition.

#### Foreign Currency Translation and Comprehensive Income (Loss)

The Company’s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into United States dollars ($) and/or USD as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency transactions are included in the statement of operations and comprehensive loss as other income (expense).

#### Research and Development Tax Credits

The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income then the Company can receive the credit which reduces its income tax liability. If the Company has net losses then the Company may still receive a cash payment for the credit, however, the Company's net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as an income tax benefit, in operations, upon receipt.

### Results of Operations for the Three Months Ended March 31, 2013 Compared to the Three Months Ended March 31, 2012

*Revenue.* For the three month periods ended March 31, 2013 and 2012, we did not generate revenues.

*Gross Profit.* Since we did not record or achieve any revenues for the three month periods ended March 31, 2013 and 2012, we did not have any costs associated with sales, and therefore we had no gross profits to report.

*Operating Expenses.* Our total operating expenses were $229,367 for the three months ended March 31, 2013, compared to $3,094,699 for the same period in 2012. This decrease was primarily caused by the amortization of stock issuance for services in 2012.

*Provision for Income Taxes.* There was no provision of tax liability for the period ending March 31, 2013 due to the Company's historical losses, however, we did record an income tax benefit relating to research and development tax concessions received.

*Net Earnings (loss).* We generated net losses of approximately $337,672 for the three months ended March 31, 2013 compared to approximately $3,096,178 for the same period in 2012. The decrease in net loss was mainly attributable to a decrease in amortization of prepaid stock issued for services in 2013 vs. 2012.

### Results of Operations for the Nine Months Ended March 31, 2013 Compared to the Nine Months Ended March 31, 2012

*Revenue.* For the nine month periods ended March 31, 2013 and 2012, we did not generate revenues.

*Gross Profit.* Since we did not record or achieve any revenues for the nine month periods ended March 31, 2013 and 2012, we did not have any costs associated with sales, and therefore we had no gross profits to report.

*Operating Expenses.* Our total operating expenses were $1,172,127 for the nine months ended March 31, 2013, compared to $9,045,343 for the same period in 2012. This decrease was primarily caused by the amortization of the stock issuance for services in 2012.

*Provision for Income Taxes.* There was no provision of tax liability for the period ending March 31, 2013, due to the Company's historical losses, however, we did record an income tax benefit relating to Research and Development tax concessions received.

*Net Earnings (Loss).* We generated net losses of approximately $1,217,990 for the nine months ended March 31, 2013, compared to approximately $8,875,611 for the same period in 2012. The decrease in net loss was mainly attributable to a decrease in amortization of prepaid stock issued for services in 2013 vs. 2012.

### Research and Development

In accordance with ASC 730-10, research and development expenditures for the Company's products are expensed when incurred, and are included in operating expenses. The Company recognized research and development costs of $1,744 and $5,317 for the nine months ended March 31, 2013 and 2012, respectively.

### Liquidity and Capital Resources

*General*. At March 31, 2013 we had a cash overdraft balance of $101. We have historically met our cash needs through a combination of proceeds from private placements of our securities and from loans. Our cash requirements are generally for operating activities. We believe that our existing cash balance will be sufficient to fund our operating activities until June 2013, although efforts are now underway for additional capital through the sale of registered securities.

Our operating activities used cash in operations of $96,701 for the nine months ended March 31, 2013, and we used cash in operations of $114,321 for the same period in 2012. The principal elements of cash flow from operations for the nine months ended March 31, 2013, included a net loss of $1,217,990, offset by depreciation expense of $978 amortization of stock based prepaid expense of $37,917, issuance of common stock for services of $797,283, loss on settlement of $107,939 and a decrease in operating working capital elements of approximately $182,100.

Cash used in investing activities during the nine months ended March 31, 2013, was $0 and $0 during the same period in 2012.

Cash received in our financing activities was $98,992 for the nine months ended March 31, 2013, compared to cash received of $153,708 during the same period in 2012. 2013 funding was related to debt financing compared to mainly convertible debt financing during 2012 which was concerted to common stock.

The Company estimates that, depending on the progress of its research and development activities, it will require approximately $7,500,000 to adequately fund operating activities and execute its development program in the next twelve to eighteen months. Presently, we do not have enough cash to continue operations for the next twelve months. If we are unable to obtain additional funds on favorable terms or at all, we may be required to delay, reduce the scope of, or eliminate one or more of our research or development programs, or to cease or reduce our operating activities.

### Going Concern

As reflected in the accompanying unaudited consolidated financial statements, for the nine months ended March 31, 2013, the Company was in the development stage, had no revenues and had a net loss of $1,217,990 and net cash used in operations of $96,701. Additionally, as of March 31, 2013, the Company had a negative cash balance, a working capital deficit of $751,551, loans in default and a deficit accumulated during development stage of $16,498,705. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on successful completion of the Company’s development program and, ultimately, the attainment of profitable operations. We can provide no assurance that we will be able to generate a sufficient amount of revenue, if any, from our business in order to achieve profitability. The unaudited consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

### Off-Balance Sheet Arrangements

We currently have no off-balance sheet arrangements.

## Controls and procedures

As filed, 1,790 characters.

### Disclosure Controls and Procedures

With the participation of our Chief Executive Officer and Chief Accounting Officer, we have evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")), as of the end of the period covered by this Report. Based upon such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such periods, our disclosure controls and procedures were not effective due to the material weakness noted below, in ensuring that (i) information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms and (ii) information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Material weakness: due to the small size of its staff, the Company did not have sufficient segregation of duties to support its internal control over financial reporting. We plan to rectify this weakness by hiring additional accounting personnel once we have additional resources to do so.

### Changes in Internal Control Over Financial Reporting

There were no changes in our internal controls over financial reporting during the quarter ended March 31, 2013, that have materially affected, or are reasonable likely to materially affect, our internal control over financial reporting.

Filed May 20, 2013.
Source: SEC EDGAR, the filing index for accession 0001354488-13-003018. Last ingested by Listed: Oct 29, 2026, 17:01 ET. No prices; not investment advice.